Top

MT-3724

MT-3724

MT-3724 is Molecular Templates’ lead drug candidate.  MT-3724 is currently in Phase 1 clinical trials at the Memorial Sloan-Kettering Cancer Center, the MD Anderson Cancer Center, the Lineberger Comprehensive Cancer Center at the University of North Carolina, and the University of Arizona.  The Phase 1 study is enrolling relapsed and refractory non-Hodgkin’s lymphoma (NHL)  patients.  More information on the Phase 1 study is available at clinicaltrials.gov.

MT-3724 is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias. Upon binding to the CD20 antigen, MT-3724 is capable of internalizing itself into the target cell. Once inside the cell, MT-3724 self-routes to the cytosol where it enzymatically and permanently shuts down ribosome function thereby directly killing the cell. This represents a unique mechanism of action in oncology. Pre-clinical studies showed potent and specific activity against CD20 expressing cells including cell lines derived from patients’ whose disease progressed after therapy with rituximab.

MT-3724 is a first-generation ETB; it is not fully de-immunized.